Testofen contains many bioactive compounds that have been carefully selected and standardised to a 50% minimum content of Fenuside
Gencor Pacific recently received a US patent for its standardised fenugreek extract, Testofen. The US patent has been granted for the improvement of sexual function, decline of sexual hormones and improvement in sexual hormonal levels in healthy ageing males.
“We have made a significant investment into the clinical validation of Testofen, and receiving this patent further progresses our commitment and intellectual property supporting this superior fenugreek extract,” said Chase Shryoc, Vice President of Sales.
“Testofen is the perfect addition for product formulations designed to support healthy sexual function and performance.”
Gencor conducted numerous double-blind placebo-controlled clinical trials to demonstrate the safety and efficacy of Testofen among healthy adult males.
The studies revealed that Testofen is a safe and effective treatment for reducing symptoms of possible androgen deficiency (increase libido, sexual desire, muscle mass), improves sexual function and increases serum testosterone in healthy middle-aged and older men.
Most recently, a double-blind, randomised, placebo-controlled study revealed that Testofen increased muscle strength, aerobic endurance and body composition in healthy exercising males, adding to the benefits and opportunities for the healthy ageing marketplace.